- Home
- FIVN vs VCEL Comparison
FIVN vs VCEL Comparison
Compare FIVN & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIVN | VCEL |
|---|---|---|
| Founded | 2001 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2014 | 1997 |
Fundamental Metrics
Financial Performance| Metric | FIVN | VCEL |
|---|---|---|
| Price | $21.07 | $36.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 6 |
| Target Price | $34.35 | ★ $60.40 |
| AVG Volume (30 Days) | ★ 1.8M | 592.9K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 236.54 |
| EPS | ★ 0.37 | 0.25 |
| Revenue | ★ $1,127,466,000.00 | $258,716,999.00 |
| Revenue This Year | $12.29 | $17.86 |
| Revenue Next Year | $9.40 | $18.55 |
| P/E Ratio | ★ $57.82 | $148.17 |
| Revenue Growth | 12.48 | ★ 14.05 |
| 52 Week Low | $17.71 | $29.24 |
| 52 Week High | $49.90 | $63.00 |
Technical Indicators
Market Signals| Indicator | FIVN | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 45.31 |
| Support Level | $19.10 | $35.85 |
| Resistance Level | $21.31 | $42.68 |
| Average True Range (ATR) | 0.67 | 1.63 |
| MACD | 0.34 | -0.32 |
| Stochastic Oscillator | 76.22 | 12.60 |
Price Performance
Historical ComparisonAbout FIVN Five9 Inc.
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Virtual Contact Center platform combines core telephony functionality, omnichannel engagement, and various modules into a unified cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, as well as workforce optimization solutions that optimize call center efficiency, and manage interaction quality and agent performance.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.